PATENT COOPERATION TREATY

PCT

Translation INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference								
664422	FOR FURTHER ACTION	See Form PCT/IPEA/416						
International application No.	International filing date (day/month/year)	Priority date (day/month/year)						
PCT/JP2004/004184	25.03.2004	28.03.2003						
International Patent Classification (IPC) or nat								
methational rational classification and free								
Applicant								
JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE								
This report is the international preli- under Article 35 and transmitted to tl	 This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 							
2. This REPORT consists of a total of	5 sheets, inclu	ading this cover sheet.						
3. This report is also accompanied by A	ANNEXES, comprising:							
a. (sent to the applicant and	d to the International Bureau) a total of	sheets, as follows:						
		•						
	sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).							
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.								
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))								
1								
	related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).							
4. This report contains indications relat	ing to the following items:							
Box No. I Basis of th	· · · · · · · · · · · · · · · · · · ·							
Box No. II Priority								
Box No. III Non-establ								
Box No. IV Lack of unity of invention								
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement								
Box No. VI Certain do								
Box No. VII Certain de	Box No. VII Certain defects in the international application							
Box No. VIII Certain observations on the international application								
Date of submission of the demand	Date of completion	of this report						
		•						
Name and mailing address of the IPEA/JP	Authorized officer	Authorized officer						
Facsimile No.	Telephone No.	Telephone No.						

International application No.
PCT/JP2004/004184

Box	No. I	Basis of the report					
1.		regard to the language, this report is based on the internation ated under this item.	al application in the language in wh	ich it was filed, unless otherwise			
		This report is based on translations from the original language into the following language which is the language of a translation furnished for the purposes of:					
		international search (Rule 12.3 and 23.1(b))					
		publication of the international application (Rule 12.4)	publication of the international application (Rule 12.4)				
		international preliminary examination (Rule 55.2 and/or 55.3)					
2.	recei	h regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the eving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to report): the international application as originally filed/furnished					
	Ħ	the description:					
	_	pages		as originally filed/furnished			
		pages*		g,			
		pages*	received by this Authority on				
		the claims:					
		nos.		as originally filed/furnished			
		nos.*	as amended (together v	vith any statement) under Article 19			
		nos.*	received by this Authority on				
		nos.*	received by this Authority on				
		the drawings:					
		sheets		as originally filed/furnished			
		sheets*	received by this Authority on				
		sheets*	received by this Authority on				
	\boxtimes	a sequence listing and/or any related table(s) - see Supplem	ental Box Relating to Sequence List	ing.			
3.		The amendments have resulted in the cancellation of:					
		the description, pages					
		the claims, nos.					
		the drawings, sheets/figs					
		the sequence listing (specify):					
4.		This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).					
		the description, pages					
		the claims, nos.					
		the drawings, sheets/figs					
		the sequence listing (specify):					
	any table(s) related to sequence listing (specify):						
*	If it	em 4 applies, some or all of those sheets may be marked "sup	erseded."				

International application No.
PCT/JP2004/004184

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
1.	Statement			
	Novelty (N)	Claims	1-11	YES
		Claims		NO
	Inventive step (IS)	Claims	1-11	YES
		Claims		мо
	Industrial applicability (IA)	Claims	1-11	YES
		Claims		NO

2. Citations and explanations (Rule 70.7)

- Document 1: WO 99/40935 Al (Juridical Foundation The Chemo-Sero-Therapeutic Research Institute),
 19 August 1999 & EP 1055429 Al & AU 9923009
- Document 2: JP 9-110704 A (Juridical Foundation The Chemo-Sero-Therapeutic Research Institute), 28 April 1997

Claims 1 to 11

The invention set forth in claims 1 to 11 is novel an involves an inventive step in relation to documents 1 and 2 cited in the international search report.

Although documents 1 and 2 indicate that Staphylococcus enteroxin B (SEB) is used in the prevention and treatment of diseases with immune abnormality, there is no mention of a SEB modification having a lowered reactivity with a neutralizing antibody to SEB.

International application No.
PCT/JP2004/004184

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

In claims 1 to 3 and 8, the "SEB modification" relating to the invention of this application is not adequately specified as a chemical substance, and is therefore unclear.

International application No.
PCT/JP2004/004184

Supplemental Box Relating to Sequence Listing Continuation of Box No. I, item 2: With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this report was established on the basis of: type of material a sequence listing table(s) related to the sequence listing format of material in written format in computer readable form time of filing/furnishing contained in the international application as filed filed together with the international application in computer readable form furnished subsequently to this Authority for the purposes of search and/or examination received by this Authority as an amendment* on In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished. Additional comments: If item 4 in Box No. I applies, the listing and/or table(s) related thereto, which form part of the basis of the report, may be marked "superseded."